SomnoMed Limited introduced Rest Assure®, its first ever inbuilt technology-enabled oral appliance. Highlights: Addresses the lack of overnight monitoring in continuous open airway therapy (`COATTM'), which has been a major barrier to prescription and reimbursement rates to date - Under the brand name Rest Assure®, sensors that measure treatment efficacy and adherence (usage) will be added to SomnoMed's milled oral appliances - Physicians and dentists will be able to view personalised data from their patients on a web-based portal, alongside a patient phone app that will allow patients to view their own sleep data - This data will help support the effectiveness equation and drive acknowledgement of equivalent clinical effectiveness for COATTM and CPAP when considering both efficacy and compliance together - Rest Assure® is expected to drive prescriptions, increased reimbursement and ultimately greater share of treatment prescriptions for COATTM versus CPAP. Currently, overnight data on usage and efficacy in the treatment of OSA is only available with CPAP devices.

Ultimately, The company expects that Rest Assure® data will help drive the acknowledgement of the clinical effectiveness for COATTM and drive greater share of therapy for COATTM versus CPAP. Once equivalent clinical effectiveness for COATTM and CPAP is quantified with objective data, this will pave the way for discussions on possible reimbursement increases for COATTM. Using Direct to Patient marketing, SomnoMed expects to build brand awareness with patients who will want to interact with the Rest Assure® patient app and request Rest Assure® by name from their sleep physician and dentist.

The Rest Assure® hardware and software is now in prototype stage, with a patient study underway to validate algorithms for efficacy and compliance. These algorithms were developed by correlating Rest Assure sensor signals and the NOX level 2 diagnostic sleep test (a portable Home Sleep Test that is a standard diagnostic test in sleep medicine). The results from this validation study will be presented at the World Sleep Meeting in Rome from March 11th-16th 2022 and will be included in CE mark and FDA regulatory submissions.

SomnoMed will continue to progress Rest Assure® towards commercial readiness. Key milestones for the remainder of fiscal year 2022 include the completion of the patient study, final design for the docking station and sensor package and the selection of suppliers. In fiscal year 2023, the Company will focus on the preparation and submission of regulatory documentation to the FDA, CE and TGA.

Ultimate commercialisation of Rest Assure® will be subject to the review and approval by these relevant regulatory authorities.